blog

Industry insights from our own scientists, publicists, developers, designers, strategists and more.

Our experts have spent their careers learning their craft, honing their skills and implementing the most effective marketing, engagement and public relations strategies to help healthcare and science brands transform the world. Let's dive in, shall we?

Featured posts

Regulatory Review: Unsung FDA approvals for rare disease in the 3rd quarter

In Q3 2022, several rare disease therapies became the first approved for their indications. Read more about under-the-radar FDA approvals for rare disease.

Katy Steele, Scientific Content Writer | October 18, 2022

FDA | FDA approved | Rare Disease

Our latest posts

Regulatory Review: Unsung FDA approvals for rare disease in the 3rd quarter

In Q3 2022, several rare disease therapies became the first approved for their indications. Read more about under-the-radar FDA approvals for rare disease.

Katy Steele, Scientific Content Writer | October 18, 2022

FDA | FDA approved | Rare Disease

A Few 2019 Wraps and 2020 Trends to Watch

We've brought together a few of our favorite year-end wrap-ups and some 2020 predictions for digital and life sciences.

HDMZ Team | January 2, 2020

FDA | Life Sciences | Patient Empowerment | Pharma | Technology

Do You Know What You're Sharing? The FDA Does.

On July 29, 2010, the FDA issued a warning letter to Novartis stating that content shared through Facebook and ShareThis functionality.

HDMZ Staff | August 12, 2010

FDA | Regulatory | Facebook | Social Media